GlassScriptPhysician profile
Allison M Swanson
NPI 1386859254
$7,637.85
in general payments reported to CMS, 2019-2025
31 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $1,556 · 2021: $1,386 · 2022: $1,457 · 2023: $761 · 2024: $162 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.49 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.27 | 2019-2023 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $719.82 | 2019-2023 | Tremfya |
| Ucb, INC. | $511.84 | 2019-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $422.82 | 2019-2024 | Dupixent |
| Lilly USA, LLC | $420.82 | 2019-2023 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $419.00 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $407.47 | 2019-2023 | Arazlo |
| Sun Pharmaceutical Industries INC. | $372.10 | 2019-2023 | Winlevi, Absorica Ld |
| Genzyme Corporation | $349.89 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $339.21 | 2019-2023 | |
| Pfizer INC. | $325.34 | 2019-2025 | |
| Amgen INC. | $309.29 | 2019-2023 | Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $300.55 | 2019-2023 | |
| Leo Pharma INC. | $221.36 | 2019-2022 | |
| Almirall LLC | $213.36 | 2019-2023 | Seysara |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $166.34 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $155.44 | 2019-2024 | |
| Dermira, INC. | $140.60 | 2019-2021 | |
| Incyte Corporation | $71.60 | 2022-2023 | Opzelura |
| Prugen, INC. Pharmaceuticals | $61.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $51.19 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $39.40 | 2023 | Vtama |
| Aclaris Therapeutics, INC. | $33.39 | 2019 | |
| Vyne Pharmaceuticals INC. | $30.83 | 2020-2021 | |
| Epi Health, LLC | $25.76 | 2019-2022 | |
| Celgene Corporation | $22.35 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.85 | 2024 | Ycanth |
| Janssen Scientific Affairs, LLC | $19.21 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.09 | 2023 | |
| Genentech USA, INC. | $13.41 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.